Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
- PMID: 23927913
- DOI: 10.1016/S0140-6736(13)61091-0
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
Abstract
Background: Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.
Methods: In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to receive either daily risedronate (2·5 or 5 mg) or placebo for 1 year. Study treatment was masked from patients, investigators, and study centre personnel. Thereafter, all children received risedronate for 2 additional years in an open-label extension. The primary efficacy endpoint was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year. The primary efficacy analysis was done by ANCOVA, with treatment, age group, and pooled centre as fixed effects, and baseline as covariate. Analyses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at least one dose of assigned study treatment. The trial is registered with ClinicalTrials.gov, number NCT00106028.
Findings: Of 147 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group. Three patients from the risedronate group and one from the placebo group did not receive study treatment, leaving 94 and 49 in the intention-to-treat population, respectively. The mean increase in lumbar spine areal BMD after 1 year was 16·3% in the risedronate group and 7·6% in the placebo group (difference 8·7%, 95% CI 5·7-11·7; p<0·0001). After 1 year, clinical fractures had occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the placebo group (p=0·0446). During years 2 and 3 (open-label phase), clinical fractures were reported in 46 (53%) of 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) of 49 patients in the group that had been given placebo during the first year. Adverse event profiles were otherwise similar between the two groups, including frequencies of reported upper-gastrointestinal and selected musculoskeletal adverse events.
Interpretation: Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Risedronate should be regarded as a treatment option for children with osteogenesis imperfecta.
Funding: Alliance for Better Bone Health (Warner Chilcott and Sanofi).
Copyright © 2013 Elsevier Ltd. All rights reserved.
Comment in
-
Oral bisphosphonates for paediatric osteogenesis imperfecta?Lancet. 2013 Oct 26;382(9902):1388-9. doi: 10.1016/S0140-6736(13)61531-7. Epub 2013 Aug 6. Lancet. 2013. PMID: 23927912 No abstract available.
Similar articles
-
Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.J Bone Miner Res. 2009 Jul;24(7):1282-9. doi: 10.1359/jbmr.090213. J Bone Miner Res. 2009. PMID: 19257821 Clinical Trial.
-
Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.Bone. 2012 Sep;51(3):383-8. doi: 10.1016/j.bone.2012.06.016. Epub 2012 Jun 30. Bone. 2012. PMID: 22750403 Clinical Trial.
-
A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.J Bone Miner Res. 2010 Jan;25(1):32-40. doi: 10.1359/jbmr.090712. J Bone Miner Res. 2010. PMID: 19580461 Clinical Trial.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2014 Jul 23;(7):CD005088. doi: 10.1002/14651858.CD005088.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Oct 19;10:CD005088. doi: 10.1002/14651858.CD005088.pub4. PMID: 25054949 Updated. Review.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4. Cochrane Database Syst Rev. 2016. PMID: 27760454 Free PMC article. Review.
Cited by
-
Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease.Mol Med. 2024 May 21;30(1):66. doi: 10.1186/s10020-024-00838-3. Mol Med. 2024. PMID: 38773377 Free PMC article.
-
Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta.J Endocrinol Invest. 2024 Nov;47(11):2785-2795. doi: 10.1007/s40618-024-02380-9. Epub 2024 May 14. J Endocrinol Invest. 2024. PMID: 38744806 Free PMC article.
-
Optimising Health-Related Quality of Life in Children With Osteogenesis Imperfecta.Calcif Tissue Int. 2024 May 2. doi: 10.1007/s00223-024-01205-4. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38695871 Review.
-
Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta.Calcif Tissue Int. 2024 Mar 29. doi: 10.1007/s00223-024-01202-7. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38553634 Review.
-
A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence.Front Endocrinol (Lausanne). 2024 Jan 25;14:1266986. doi: 10.3389/fendo.2023.1266986. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38374961 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
